» Articles » PMID: 22355301

The C Proteins of Human Parainfluenza Virus Type 1 Block IFN Signaling by Binding and Retaining Stat1 in Perinuclear Aggregates at the Late Endosome

Overview
Journal PLoS One
Date 2012 Feb 23
PMID 22355301
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Interferons (IFNs) play a crucial role in the antiviral immune response. Whereas the C proteins of wild-type human parainfluenza virus type 1 (WT HPIV1) inhibit both IFN-β induction and signaling, a HPIV1 mutant encoding a single amino acid substitution (F170S) in the C proteins is unable to block either host response. Here, signaling downstream of the type 1 IFN receptor was examined in Vero cells to define at what stage WT HPIV1 can block, and F170S HPIV1 fails to block, IFN signaling. WT HPIV1 inhibited phosphorylation of both Stat1 and Stat2, and this inhibition was only slightly reduced for F170S HPIV1. Degradation of Stat1 or Stat2 was not observed. The HPIV1 C proteins were found to accumulate in the perinuclear space, often forming large granules, and co-localized with Stat1 and the cation-independent mannose 6-phosphate receptor (M6PR) that is a marker for late endosomes. Upon stimulation with IFN-β, both the WT and F170S C proteins remained in the perinuclear space, but only the WT C proteins prevented Stat1 translocation to the nucleus. In addition, WT HPIV1 C proteins, but not F170S C proteins, co-immunoprecipitated both phosphorylated and unphosphorylated Stat1. Our findings suggest that the WT HPIV1 C proteins form a stable complex with Stat1 in perinuclear granules that co-localize with M6PR, and that this direct interaction between the WT HPIV1 C proteins and Stat1 is the basis for the ability of HPIV1 to inhibit IFN signaling. The F170S mutation in HPIV1 C did not prevent perinuclear co-localization with Stat1, but apparently weakened this interaction such that, upon IFN stimulation, Stat1 was translocated to the nucleus to induce an antiviral response.

Citing Articles

Respiratory syncytial virus NS1 inhibits anti-viral Interferon-α-induced JAK/STAT signaling, by limiting the nuclear translocation of STAT1.

Efstathiou C, Zhang Y, Kandwal S, Fayne D, Molloy E, Stevenson N Front Immunol. 2024; 15:1395809.

PMID: 38938568 PMC: 11208467. DOI: 10.3389/fimmu.2024.1395809.


Type I and Type II Interferon Antagonism Strategies Used by : Previous and New Discoveries, in Comparison.

Pisanelli G, Pagnini U, Iovane G, Garcia-Sastre A Viruses. 2022; 14(5).

PMID: 35632848 PMC: 9145045. DOI: 10.3390/v14051107.


A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.

Chakraborty C, Sharma A, Bhattacharya M, Lee S Front Immunol. 2022; 13:801522.

PMID: 35222380 PMC: 8863680. DOI: 10.3389/fimmu.2022.801522.


Acute Infection of Viral Pathogens and Their Innate Immune Escape.

Rai K, Shrestha P, Yang B, Chen Y, Liu S, Maarouf M Front Microbiol. 2021; 12:672026.

PMID: 34239508 PMC: 8258165. DOI: 10.3389/fmicb.2021.672026.


Human Type I Interferon Antiviral Effects in Respiratory and Reemerging Viral Infections.

Acosta P, Byrne A, Hijano D, Talarico L J Immunol Res. 2020; 2020:1372494.

PMID: 32455136 PMC: 7231083. DOI: 10.1155/2020/1372494.


References
1.
Itoh M, Isegawa Y, Hotta H, Homma M . Isolation of an avirulent mutant of Sendai virus with two amino acid mutations from a highly virulent field strain through adaptation to LLC-MK2 cells. J Gen Virol. 1997; 78 ( Pt 12):3207-15. DOI: 10.1099/0022-1317-78-12-3207. View

2.
Kato A, Ohnishi Y, Hishiyama M, Kohase M, Saito S, Tashiro M . The amino-terminal half of Sendai virus C protein is not responsible for either counteracting the antiviral action of interferons or down-regulating viral RNA synthesis. J Virol. 2002; 76(14):7114-24. PMC: 136303. DOI: 10.1128/jvi.76.14.7114-7124.2002. View

3.
Gosselin-Grenet A, Marq J, Abrami L, Garcin D, Roux L . Sendai virus budding in the course of an infection does not require Alix and VPS4A host factors. Virology. 2007; 365(1):101-12. DOI: 10.1016/j.virol.2007.03.039. View

4.
Zuniga E, Hahm B, Oldstone M . Type I interferon during viral infections: multiple triggers for a multifunctional mediator. Curr Top Microbiol Immunol. 2007; 316:337-57. DOI: 10.1007/978-3-540-71329-6_16. View

5.
Stojdl D, Lichty B, tenOever B, Paterson J, Power A, Knowles S . VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003; 4(4):263-75. DOI: 10.1016/s1535-6108(03)00241-1. View